Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma

Health-related quality of life was a secondary endpoint in the phase III GALLIUM study in previously untreated patients with follicular lymphoma who were treated with rituximab- or obinutuzumab-chemotherapy. Patients were randomized 1:1 to receive induction therapy with obinutuzumab- or rituximab-ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Andrew, Trask, Peter, Demeter, Judit, Florschütz, Axel, Hänel, Mathias, Kinoshita, Tomohiro, Pettengell, Ruth, Quach, Hang, Robinson, Stephen, Sadullah, Shalal, Sancho, Juan-Manuel, Udvardy, Miklos, Witzens-Harig, Mathias, Knapp, Andrea, Liu, Wenxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683459/
https://www.ncbi.nlm.nih.gov/pubmed/32314038
http://dx.doi.org/10.1007/s00277-020-04021-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683459/
https://www.ncbi.nlm.nih.gov/pubmed/32314038
http://dx.doi.org/10.1007/s00277-020-04021-6

Ejemplares similares